Trial 3L-17-1


A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRS Specific for Alpha Fetoprotein (AFPC332T) in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC) or any other AFP expressing tumor types

Type: Treatment
Phase: Phase I
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Other
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Victoria Amran, Coordinator, Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Anayansi Miloud, D.M., Marile Garcia, Coordinator, Melissa Wallman, Coordinator, Yanli Wang, D.M., Rabia Rehman, Coordinator, Apoorva Vishwanath, D.M., Angela Smith Bryant, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.